You might think lower doses mean worse outcomes
Armbrecht HJ, Hodam TL, Boltz MA (2003) Hormonal regulation of 25-hydroxyvitamin D 31a-hydroxylase and 24-hydroxylase gene transcription in opossum kidney cells
For more information: Tyler Baba, Investor Relations, Manager, WELL Health Technologies, [email protected], 604-628-7266
Retatrutide is an investigational GLP-1/GIP/glucagon triple agonist with no MHRA, EMA, or FDA marketing authorisation
the boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies and applies to compounded versions of both molecules as well
To learn more, visit their sites